GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » YoY EPS Growth

Biomarin Pharmaceutical (WBO:BMRN) YoY EPS Growth : 107.80% (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Biomarin Pharmaceutical YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Biomarin Pharmaceutical's YoY EPS Growth for the quarter that ended in Mar. 2025 was 107.80%.

Biomarin Pharmaceutical's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was €0.88.

Biomarin Pharmaceutical YoY EPS Growth Historical Data

The historical data trend for Biomarin Pharmaceutical's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical YoY EPS Growth Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,261.54 -108.38 328.39 12.71 164.54

Biomarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.86 90.67 151.78 504.95 107.80

Biomarin Pharmaceutical YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Biomarin Pharmaceutical's YoY EPS Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EPS Growth (A: Dec. 2024 )
=(Earnings per Share (Diluted) (A: Dec. 2024 )-Earnings per Share (Diluted) (A: Dec. 2023 ))/ | Earnings per Share (Diluted) (A: Dec. 2023 ) |
=(2.111-0.798)/ | 0.798 |
=164.54 %

Biomarin Pharmaceutical's YoY EPS Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EPS Growth (Q: Mar. 2025 )
=(Earnings per Share (Diluted) (Q: Mar. 2025 )-Earnings per Share (Diluted) (Q: Mar. 2024 )) / | Earnings per Share (Diluted) (Q: Mar. 2024 )) |
=(0.879-0.423)/ | 0.423 |
=107.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » YoY EPS Growth
Comparable Companies
INSM INCY MRNA RPRX EXEL ASND TECH ROIV CORT HALO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
BMRN:USA BMRN:Mexico 1BMRN:Italy 0HNC:UK BM8:Germany BM8:Germany B1MR34:Brazil
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
https://www.biomarin.com
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.